# PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer

> **NCT07130344** · NA · NOT_YET_RECRUITING · sponsor: **Centre Paul Strauss** · enrollment: 262 (estimated)

## Conditions studied

- Metastatic Breast Cancer
- HER 2 Low-expressing Breast Cancer

## Interventions

- **PROCEDURE:** TAP CT-scan
- **PROCEDURE:** Bone scintigraphy
- **PROCEDURE:** 18F-FDG PET-CT

## Key facts

- **NCT ID:** NCT07130344
- **Lead sponsor:** Centre Paul Strauss
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2028-12
- **Final completion:** 2030-09
- **Target enrollment:** 262 (ESTIMATED)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07130344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07130344, "PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07130344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*